Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1986 2
1987 1
1989 1
1991 1
1996 2
1999 1
2004 1
2005 4
2006 5
2007 6
2008 4
2009 4
2010 2
2011 4
2012 6
2013 10
2014 4
2015 12
2016 12
2017 17
2018 12
2019 15
2020 23
2021 30
2022 42
2023 43
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

233 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following terms were ignored: %, %, %, %
The following terms were not found in PubMed: 22Davradou, 5BAuthor
Page 1
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
Monk BJ, Tewari KS, Dubot C, Caceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş M, Hurtado de Mendoza MO, Samouëlian V, Castonguay V, Arkhipov A, Tekin C, Li K, Martin Nguyen A, Monberg MJ, Colombo N, Lorusso D. Monk BJ, et al. Lancet Oncol. 2023 Apr;24(4):392-402. doi: 10.1016/S1470-2045(23)00052-9. Epub 2023 Mar 3. Lancet Oncol. 2023. PMID: 36878237 Clinical Trial.
Patients were randomly assigned (1:1) centrally by means of an interactive voice response system in a double-blind manner to receive either pembrolizumab 200 mg or placebo every 3 weeks intravenously for up to 35 cycles plus chemotherapy (paclitaxel 175 mg/m(2) plus cispla …
Patients were randomly assigned (1:1) centrally by means of an interactive voice response system in a double-blind manner to receive either …
[Asthenic post-COVID syndrome].
Khaibullina DK, Maksimov YN. Khaibullina DK, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(3):61-69. doi: 10.17116/jnevro202312303161. Zh Nevrol Psikhiatr Im S S Korsakova. 2023. PMID: 36946399 Russian.
Before the start of the study, in addition to a physical examination, the patient's condition was assessed using the following questionnaires and scales: VAS for asthenia, subjective scale for assessing asthenia (MFI-20), L.D. Malkova, a questionnaire for the quality of life (EQ- …
Before the start of the study, in addition to a physical examination, the patient's condition was assessed using the following questionnaire …
Uptitrating Treatment After Heart Failure Hospitalization Across the Spectrum of Left Ventricular Ejection Fraction.
Pagnesi M, Metra M, Cohen-Solal A, Edwards C, Adamo M, Tomasoni D, Lam CSP, Chioncel O, Diaz R, Filippatos G, Ponikowski P, Sliwa K, Voors AA, Kimmoun A, Novosadova M, Takagi K, Barros M, Damasceno A, Saidu H, Gayat E, Pang PS, Celutkiene J, Cotter G, Mebazaa A, Davison B. Pagnesi M, et al. J Am Coll Cardiol. 2023 Jun 6;81(22):2131-2144. doi: 10.1016/j.jacc.2023.03.426. J Am Coll Cardiol. 2023. PMID: 37257948 Clinical Trial.
The treatment benefit of high-intensity care vs usual care on the primary endpoint was consistent across the whole LVEF spectrum (interaction P with LVEF as a continuous variable = 0.372). Mean difference in the EQ-5D visual analog scale change from baseline to day 90 betw …
The treatment benefit of high-intensity care vs usual care on the primary endpoint was consistent across the whole LVEF spectrum (interactio …
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.
Aldred J, Freire-Alvarez E, Amelin AV, Antonini A, Bergmans B, Bergquist F, Bouchard M, Budur K, Carroll C, Chaudhuri KR, Criswell SR, Danielsen EH, Gandor F, Jia J, Kimber TE, Mochizuki H, Robieson WZ, Spiegel AM, Standaert DG, Talapala S, Facheris MF, Fung VSC. Aldred J, et al. Neurol Ther. 2023 Dec;12(6):1937-1958. doi: 10.1007/s40120-023-00533-1. Epub 2023 Aug 26. Neurol Ther. 2023. PMID: 37632656 Free PMC article.
Secondary endpoints included changes from baseline in normalized "Off" and "On" time, percentage of patients reporting morning akinesia, Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Parkinson's Disease Sleep Scale-2 (PDSS-2), 39-item Parkinson's …
Secondary endpoints included changes from baseline in normalized "Off" and "On" time, percentage of patients reporting morning akinesia, Mov …
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T, Amonkar M, Norquist JM, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt CJA, Smith D, Garcia-Carbonero R, Sevilla I, De La Fouchardiere C, Rivera F, Elez E, Diaz LA Jr, Yoshino T, Van Cutsem E, Yang P, Farooqui M, Le DT. Andre T, et al. Lancet Oncol. 2021 May;22(5):665-677. doi: 10.1016/S1470-2045(21)00064-4. Epub 2021 Apr 1. Lancet Oncol. 2021. PMID: 33812497 Clinical Trial.
HRQOL outcomes were mean change from baseline to prespecified week 18 in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and EORTC Quality of Life Questionnaire-Colorectal 29 (EORTC QLQ-CR29) scale and item scores, …
HRQOL outcomes were mean change from baseline to prespecified week 18 in European Organisation for Research and Treatment of Cancer Quality …
Vacuum-deposited Rb3CeI6 for deep-blue-light-emitting diodes.
Du H, Yang L, Pang J, Shen Z, Li J, Dong X, Luo Y, Luo J, Tang J. Du H, et al. Opt Lett. 2023 Jun 1;48(11):2777-2780. doi: 10.1364/OL.486168. Opt Lett. 2023. PMID: 37262208
Herein, we vacuum thermally deposited a film of the lead-free rare earth halide Rb(3)CeI(6), which shows deep blue emission with peaks at 427 nm and 468 nm. Due to the parity-allowed 5d-4f transition of Ce(III), the excited-state lifetime is as short as 22.3 ns (427 …
Herein, we vacuum thermally deposited a film of the lead-free rare earth halide Rb(3)CeI(6), which shows deep blue emission with peaks at 42 …
Creating a Health Utility Value for Birdshot Chorioretinopathy.
Sekaran A, Shamdas M, Barry RJ, Denniston AK, Murray PI. Sekaran A, et al. Ocul Immunol Inflamm. 2022 Jan 2;30(1):73-80. doi: 10.1080/09273948.2020.1799034. Epub 2020 Sep 18. Ocul Immunol Inflamm. 2022. PMID: 32946293
RESULTS: A total of 28 BCR patients (9 M, 19 F; mean age 62 years, range 47-83) were included. There were 22 patients with a logMAR vision of 0.3 or better in both eyes. Mean TTO was 0.90 SD 0.18 (range 0.33-1.0) and mean SG was 0.94 SD 0.14 (range 0.5-1.0). TTO cor …
RESULTS: A total of 28 BCR patients (9 M, 19 F; mean age 62 years, range 47-83) were included. There were 22 patients with a l …
A systematic review of patient-reported outcome measures for advanced skin cancer patients.
Reinhardt ME, Sun T, Pan CX, Schmults CD, Lee EH, Waldman AB. Reinhardt ME, et al. Arch Dermatol Res. 2023 Aug;315(6):1473-1480. doi: 10.1007/s00403-022-02479-0. Epub 2022 Dec 5. Arch Dermatol Res. 2023. PMID: 36469125 Review.
A total of 1,998 articles were identified. 82 met our inclusion criteria resulting in 22 PROMs: five generic health-related (QWB-SA, AQoL-8D, EQ-5D, SF-36, and PRISM), six general cancer (EORTC QLQ-C30, EORTC QLQ-C36, LASA, IOC, Rotterdam Symptom Checklist, and FACT …
A total of 1,998 articles were identified. 82 met our inclusion criteria resulting in 22 PROMs: five generic health-related (QWB-SA, …
Trimetazidine in heart failure with preserved ejection fraction: a randomized controlled cross-over trial.
van de Bovenkamp AA, Geurkink KTJ, Oosterveer FTP, de Man FS, Kok WEM, Bronzwaer PNA, Allaart CP, Nederveen AJ, van Rossum AC, Bakermans AJ, Handoko ML. van de Bovenkamp AA, et al. ESC Heart Fail. 2023 Oct;10(5):2998-3010. doi: 10.1002/ehf2.14418. Epub 2023 Aug 2. ESC Heart Fail. 2023. PMID: 37530098 Free PMC article. Clinical Trial.
The study included 25 patients (10/15 males/females; mean (standard deviation) age, 66 (10) years; body mass index, 29.8 (4.5) kg/m(2) ); with the diagnosis of HFpEF confirmed with (exercise) right heart catheterization either before or during the trial. ...There was no ch …
The study included 25 patients (10/15 males/females; mean (standard deviation) age, 66 (10) years; body mass index, 29.8 (4.5) kg/m(2 …
Diagnosis and outcomes of cachexia in Asia: Working Consensus Report from the Asian Working Group for Cachexia.
Arai H, Maeda K, Wakabayashi H, Naito T, Konishi M, Assantachai P, Auyeung WT, Chalermsri C, Chen W, Chew J, Chou MY, Hsu CC, Hum A, Hwang IG, Kaido T, Kang L, Kamaruzzaman SB, Kim M, Lee JSW, Lee WJ, Liang CK, Lim WS, Lim JY, Lim YP, Lo RS, Ong T, Pan WH, Peng LN, Pramyothin P, Razalli NH, Saitoh M, Shahar S, Shi HP, Tung HH, Uezono Y, von Haehling S, Won CW, Woo J, Chen LK. Arai H, et al. J Cachexia Sarcopenia Muscle. 2023 Oct;14(5):1949-1958. doi: 10.1002/jcsm.13323. Epub 2023 Sep 5. J Cachexia Sarcopenia Muscle. 2023. PMID: 37667992 Free PMC article. Review.
The AWGC proposed a significant weight change of 2% or more over a 3-6 month period and suggested a tentative cut-off value of 21 kg/m(2) for low body mass index in diagnosing cachexia. Critical clinical outcomes were determined to be mortality, quality of life as assessed …
The AWGC proposed a significant weight change of 2% or more over a 3-6 month period and suggested a tentative cut-off value of 21 kg/m
233 results